Unique interplay between tumor and blood vessel cells promotes angiogenesis and tumor growth

July 18, 2005

Scientists now have a more complete understanding of how cancer cells send signals to surrounding tissues to promote development of the blood supply needed to support tumor growth. For the first time, it has been shown that signals expressed by tumor cells can directly interact with the outer membrane of adjacent blood vessel cells and influence growth and development. The research, published in the July issue of Cancer Cell, may provide a new and more efficient target for antiangiogenic therapy.

Tumor cells, like other cells, require blood vessels to deliver oxygen and nutrients and to remove waste. Scientists have known for some time that tumor cells can stimulate blood vessel growth by secreting growth factors that promote angiogenesis. However, most human cancer therapies based on targeting these factors have been less than successful. Dr. Cun-Yu Wang from the University of Michigan and colleagues designed a series of studies to search for other signals that play a critical role in tumor angiogenesis.

The researchers examined factors that were upregulated when cancer cells were stimulated with a known growth factor. They found that angiogenic factors stimulated the mitogen-activated protein kinase (MAPK) pathway to induce the Notch ligand Jagged1 in head and neck squamous cell carcinoma cells. Jagged1 triggered Notch activation in neighboring blood vessel cells and promoted formation of new vessels. Notch signaling is known to be critical for specification of cell fate during development, and there is evidence that Notch plays a role in blood vessel formation. Angiogenesis and tumor growth was significantly enhanced in Jagged1-expressing cancer cells and high levels of Jagged1 were correlated with tumor size and blood vessel content.

Although Notch activation alone in tumor cells was not sufficient to induce angiogenesis, elevated levels of Jagged initiated crosstalk between tumor cells and blood vessel cells and stimulated tumor growth and new blood vessel formation. "Our studies suggest that in addition to the secretion of proangiogenic growth factors, tumor cells may express Notch ligands to guide angiogenesis which supports tumor growth and progression," explains Dr. Wang. "Our results elucidate a novel mechanism by which the direct interplay between tumor cells and blood vessel cells promotes angiogenesis through MAPK and Notch signaling pathways."
The researchers include Qinghua Zeng, Douglas B. Chepeha, Thomas J. Giordano, Jong Li, Honglai Zhang, Cun-Yu Wang, Peter J. Polverini, and Jacques Nor of School of Dentistry and Medicine, University of Michigan, Ann Arbor; Shenglin Li of Peking University School of Stomatology; and Jan Kitajewski of Columbia University, College of Physicians and Surgeons, New York. This work was supported by NIH grants and by the Chang Jiang Scholar Program.

Qinghua Zeng, Shenglin Li, Douglas B. Chepeha, Thomas J. Giordano, Jong Li, Honglai Zhang, Peter J. Polverini, Jacques Nor, Jan Kitajewski, and Cun-Yu Wang: "Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling" Publishing in Cancer Cell, Vol. 8, July 2005, pages 13-23 . DOI 10.1016/j.ccr.2005.06.004 www.cancercell.org

Cell Press

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.